A recent analysis found that the government could have saved roughly $14 billion on the top 50 drugs covered by Medicare Part D in 2016 if the program negotiated drugmakers down to prices paid by the Department of Veterans Affairs, STAT reports.
Part D, according to the report, could have saved about $1.3 billion on Gilead’s hepatitis C treatment, Harvoni. The program spent about $3 billion on the drug in 2016, while the VA negotiated the price down to around $1.7 billion.
Per the report, the program could have saved about $600 million on Celgene’s Revlimid with VA prices.
To read the full report on STAT, click here.